z-logo
open-access-imgOpen Access
Investigation of the bismuth oxide nanoparticles on bystander effect in MCF-7 and hFOB 1.19 cells
Author(s) -
Nur Hamizah Mohd Zainudin,
Khairunisak Ab Razak,
Safri Zainal Abidin,
Norhayati Dollah,
Wan Nordiana Rahman
Publication year - 2020
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1497/1/012017
Subject(s) - bystander effect , irradiation , bismuth , cell culture , viability assay , incubation , cell , chemistry , materials science , immunology , medicine , biology , biochemistry , physics , organic chemistry , nuclear physics , genetics
This study aims to investigate the effect of bismuth oxide nanoparticles (Bi 2 O 3 NPs) on the radiation induced bystander effect (RIBE) in MCF-7 and hFOB 1.19 cells line. The cells were irradiated with radiation doses of 0 to 12 Gy using 6 MV photon beam in a single exposure. The irradiated cells’ culture media were transferred to non-irradiated bystander cells 1 hour post-irradiation. PrestoBlue assay was then performed in this experiment to assess the cells’ viability. Results of cell viability percentage in all bystander cell groups compared to the control showed no significant differences (P > 0.05) for both MCF-7 and hFOB 1.19 cell lines. The test also revealed no radiation dose dependencies for all bystander cells groups. The present study demonstrated that MCF-7 and hFOB 1.19 bystander cells were able to proliferate (> 80%) after 48 hours incubation with irradiated-cell conditioned medium (ICCM) treated with Bi 2 O 3 NPs. In summary, the use of Bi 2 O 3 NPs for radiosensitization in radiotherapy is safe and do not increase the RIBE responses in non-targeted cells. RIBE remained as one of the most crucial factors that need to be address and considered for the application of nanoparticles as radiosensitizers in radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here